When looking at adverse side effects, it should also be remembered that in the historical trials the bisantrene dose was much higher than will be used in the upcoming breast cancer cardioprotection trial.
- Forums
- ASX - By Stock
- RAC
- Ann: Ethics submission to commence cardioprotection trial
Ann: Ethics submission to commence cardioprotection trial, page-42
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M |
Open | High | Low | Value | Volume |
$1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 31396 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.440 |
1 | 11250 | 1.390 |
1 | 1000 | 1.380 |
1 | 5000 | 1.370 |
1 | 1279 | 1.365 |
Price($) | Vol. | No. |
---|---|---|
1.450 | 31396 | 1 |
1.480 | 3055 | 2 |
1.500 | 17040 | 2 |
1.520 | 6000 | 1 |
1.575 | 2000 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online